Literature DB >> 8109919

Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.

P A Bradford1, C C Sanders.   

Abstract

A predictor panel of clinical isolates that produce a variety of types and amounts of beta-lactamases was used to assess the accuracy of dilution and disk diffusion susceptibility tests for piperacillin-tazobactam. Combinations of piperacillin-tazobactam with a fixed ratio of 8:1 and with tazobactam held constant at 4 micrograms/ml were examined in dilution tests performed in agar. In addition, disks containing 100 and 10 micrograms of piperacillin and tazobactam, respectively, were examined in diffusion tests. Three very major discrepancies between MICs determined with an 8:1 ratio and MICs determined with tazobactam held constant at 4 micrograms/ml were noted. These involved strains that appeared to be susceptible in tests with the 8:1 ratio but resistant when tazobactam was held constant at 4 micrograms/ml. However, the differences were only twofold. Error rate-bounded analysis with the disk containing 100 and 10 micrograms of piperacillin and tazobactam, respectively, revealed low error rates, regardless of whether MICs were determined with an 8:1 ratio or tazobactam held constant at 4 micrograms/ml. Thus, a predictor panel was useful in the identification of accurate susceptibility test for piperacillin-tazobactam.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109919      PMCID: PMC192743          DOI: 10.1128/AAC.37.12.2578

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

4.  Characterization of beta-lactamases in situ on polyacrylamide gels.

Authors:  C C Sanders; W E Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

5.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

7.  Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

8.  In vitro activity and disk susceptibility of Timentin: current status.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  Am J Med       Date:  1985-11-29       Impact factor: 4.965

9.  Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

10.  In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

View more
  3 in total

1.  A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Authors:  Patricia A Bradford; Michael D Huband; Gregory G Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.

Authors:  William J Weiss; Peter J Petersen; Timothy M Murphy; Luanna Tardio; Youjun Yang; Patricia A Bradford; Aranapakam M Venkatesan; Takao Abe; Takeshi Isoda; Ado Mihira; Hideki Ushirogochi; Tsuyoshi Takasake; Steve Projan; John O'Connell; Tarek S Mansour
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Tarek S Mansour; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.